Loading...
Loading...
India's nilotinib imports from UNITED STATES total $822.9K across 47 shipments from 15 foreign suppliers. Espee Biopharma & Finechem LLC leads with $191.5K in import value; the top 5 suppliers together control 75.1% of this origin. Leading Indian buyers include HETERO LABS LIMITED. This corridor reflects India's pharmaceutical import demand for nilotinib — a diversified sourcing base with multiple active suppliers from UNITED STATES.

Espee Biopharma & Finechem LLC is the leading Nilotinib supplier from UNITED STATES to India, with import value of $191.5K across 4 shipments. The top 5 suppliers — Espee Biopharma & Finechem LLC, ESPEE BIOPHARMA & FINECHEM LLC, M/S. SUNSOURCE PHARMACEUTICALS, NEWLIFE MEDICALS (USA). INC., ESPEE BIOPHARMA FINECHEM LLC — collectively account for 75.1% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | Espee Biopharma & Finechem LLC | $191.5K | 4 | 23.3% |
| 2 | ESPEE BIOPHARMA & FINECHEM LLC | $163.7K | 5 | 19.9% |
| 3 | M/S. SUNSOURCE PHARMACEUTICALS | $118.8K | 3 | 14.4% |
| 4 | NEWLIFE MEDICALS (USA). INC. | $81.3K | 1 | 9.9% |
| 5 | ESPEE BIOPHARMA FINECHEM LLC | $63.0K | 1 | 7.7% |
| 6 | Pharmaceutical Buyers, Inc. | $40.8K | 1 | 5.0% |
| 7 | NEW LIFE MEDICALS (USA),INC | $36.0K | 1 | 4.4% |
| 8 | ESPEE BIOPHARMA & FINECHEM LLC. | $21.8K | 1 | 2.6% |
| 9 | AMSTERDAM PHARMA(APTEKA RX INC.) | $20.5K | 1 | 2.5% |
| 10 | PHARMACEUTICAL BUYERS INC | $20.5K | 1 | 2.5% |
| 11 | M/S. PHARMACEUTICAL BUYERS, INC | $20.3K | 1 | 2.5% |
| 12 | AGRACE PHARMA. | $20.1K | 1 | 2.4% |
| 13 | JUPITER RESEARCH SERVICES INC | $20.0K | 1 | 2.4% |
| 14 | SIGMAPHARM LABORATORIES, LLC | $3.0K | 8 | 0.4% |
| 15 | UPM PHARMACEUTICALS | $1.1K | 8 | 0.1% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | HETERO LABS LIMITED | $138.1K | 3 | 16.8% |
| 2 | EUGIA PHARMA SPECIALITIES LIMITED | $121.4K | 3 | 14.8% |
| 3 | NATCO PHARMA LIMITED | $118.8K | 3 | 14.4% |
| 4 | TORRENT PHARMACEUTICALS LTD | $88.4K | 2 | 10.7% |
| 5 | CIPLA LIMITED | $63.0K | 1 | 7.7% |
| 6 | AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED | $61.2K | 2 | 7.4% |
| 7 | DR.REDDY'S LABORATORIES LTD | $60.6K | 3 | 7.4% |
| 8 | ZENRISE CLINICAL RESEARCH PRIVATE LIMITED | $53.5K | 4 | 6.5% |
| 9 | VEEDA CLINICAL RESEARCH LIMITED | $36.0K | 1 | 4.4% |
| 10 | SLAYBACK PHARMA INDIA LLP | $35.2K | 2 | 4.3% |
| 11 | CIPLA LIMITED. | $21.8K | 1 | 2.6% |
| 12 | NORWICH CLINICAL SERVICES PRIVATE LIMITED | $20.3K | 1 | 2.5% |
| 13 | ECRON ACUNOVA LIMITED | $2.9K | 7 | 0.4% |
| 14 | QPS BIOSERVE INDIA PRIVATE LIMITED | $1.2K | 11 | 0.1% |
| 15 | LAMBDA THERAPEUTIC RESEARCH LIMITED | $211 | 1 | 0.0% |
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Nilotinib suppliers from UNITED STATES to India include Espee Biopharma & Finechem LLC, ESPEE BIOPHARMA & FINECHEM LLC, M/S. SUNSOURCE PHARMACEUTICALS. The leading supplier is Espee Biopharma & Finechem LLC with import value of $191.5K USD across 4 shipments. India imported Nilotinib worth $822.9K USD from UNITED STATES in total across 47 shipments.
India imported Nilotinib worth $822.9K USD from UNITED STATES across 47 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Nilotinib sourced from UNITED STATES include HETERO LABS LIMITED, EUGIA PHARMA SPECIALITIES LIMITED, NATCO PHARMA LIMITED. The largest buyer is HETERO LABS LIMITED with $138.1K in imports across 3 shipments.
The total value of Nilotinib imports from UNITED STATES to India is $822.9K USD, across 47 shipments and 15 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
47 Verified Shipments
15 suppliers, 15 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists